Trial Profile

A Phase 2 Dose Optimization Trial Evaluating a CD46-Targeted Antibody-Drug Conjugate (FG-3246) in Patients With Metastatic Castration-Resistant Prostate Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FG 3180 (Primary) ; FG 3246 (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Sponsors Kyntra Bio

Most Recent Events

07 Jan 2026 According to FibroGen media release, FibroGen is now called as Kyntra Bio.
17 Dec 2025 Planned initiation date changed from 30 Nov 2025 to 1 Jan 2026.
31 Oct 2025 Planned initiation date changed from 15 Sep 2025 to 30 Nov 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com